Partial least square discriminant analysis was used to identify discriminant metabolite features, and the diagnostic performance of selected classifiers was quantified using AUROC curve analysis
Technology and Potential Benefits DehydraTECH is Lexaria's patented drug delivery platform designed to improve oral drug bio-absorption and reduce side effects
A phase III, randomized, double-blind, parallel-group study showed that the combination of SGLT2 inhibitors and DPP-4 inhibitors resulted in the reductions of HbA1c (mean baseline 7.908.02% [62.864.1 mmol/mol]), FPG, serum uric acid, SBP, and hypoglycemic risk were superior to those with the individual components in patients with T2DM
These effects are transient, usually resolving within a week of the dose change
As a single working mom raising three teenagers and a dog, that's been hard to put a price on